Peptide Education Manager
Edit KLOW
Name
Scientific / Common Name
Alternative Names
Slug (url-safe, unique)
Short Description (shown on cards)
A four-peptide combination expanding on aesthetic and tissue-repair research with the addition of the anti-inflammatory peptide KPV.
Overview — What Is It? (paragraphs)
KLOW builds on the same conceptual foundation as GLOW by adding a fourth peptide, KPV, to the GHK-Cu, BPC-157, and TB-500 combination. KPV is a short peptide fragment derived from a melanocortin-related protein and has been studied in laboratory settings for its proposed anti-inflammatory signaling, particularly related to cytokine activity. The four peptides in KLOW each have separate, individual research histories. The specific four-ingredient combined formulation has not itself been studied in dedicated clinical research. As with GLOW, the inclusion of multiple actively-researched ingredients does not mean the combined product has been clinically validated as a single formulation.
Why Being Studied (one item per line)
Anti-inflammatory cytokine signaling (KPV) Skin collagen and elasticity signaling (GHK-Cu) Tissue repair pathways (BPC-157, TB-500) Combined inflammatory and regenerative research interest
How It May Work
KPV is proposed to act on melanocortin receptor signaling to reduce activity of NF-κB, a pathway involved in producing inflammatory cytokines. This mechanism is combined with GHK-Cu's proposed role in collagen signaling and BPC-157/TB-500's proposed role in tissue repair. The combined mechanism of the four-peptide formulation together has not been independently studied.
Mechanism Pathway Steps (one per line)
KLOW blend Melanocortin/NF-κB signaling + collagen & repair pathways Reduced inflammatory cytokine activity & tissue remodeling Aesthetic & anti-inflammatory outcomes under study
Evidence Rating
Established / Approved Use
Strong Human Evidence
Moderate Human Evidence
Early Human Evidence
Preclinical Evidence
Emerging / Limited Evidence
Human Evidence
Human clinical data on the specific four-peptide KLOW formulation is not available. KPV has limited laboratory-stage research related to inflammatory signaling.
Preclinical Evidence
Laboratory research on KPV has examined its effects on inflammatory cytokine markers in cell and animal models. The other three ingredients have their own separate preclinical research bases.
What We Don't Know Yet
Whether this four-peptide combination produces effects different from its individual ingredients has not been studied. Long-term human safety data for this specific blend is not available.
Research Area Cards (format: Title: description — one per line)
Skin & Aesthetics: GHK-Cu contributes a collagen and skin-remodeling research angle to this formulation. Inflammatory Signaling: KPV's proposed effect on inflammatory cytokines is the primary addition compared to GLOW. Recovery: BPC-157 and TB-500 contribute tissue-repair research interest.
Why Might Someone Discuss This With Their Provider?
Someone researching inflammatory signaling alongside aesthetic and recovery peptide combinations may encounter KLOW while comparing combination formulations.
Regulatory Status
No ingredient in this formulation is FDA-approved for the uses being researched, and the combined KLOW product is not an FDA-approved drug product.
Important Considerations
This is a combination product with four active ingredients. Evidence for any individual ingredient does not establish evidence for this specific blended formulation. Discuss combination peptide products with a licensed healthcare provider.
Related Peptide Slugs (one per line)
glow bpc-157 bpc-157-tb-500
Is Combination Product?
Combination Ingredients (format: Name: description — one per line)
KPV: A short melanocortin-derived peptide studied in laboratory research for its proposed effect on inflammatory cytokine signaling, including NF-κB-related pathways. GHK-Cu: A naturally occurring copper-binding tripeptide studied for its relationship to collagen synthesis and skin remodeling. BPC-157: A peptide studied in animal models for its proposed role in tissue repair and regenerative signaling. TB-500: A synthetic fragment related to thymosin beta-4, studied in laboratory settings for its proposed role in cell migration and tissue repair.
Why Are These Combined?
KLOW adds KPV to the GLOW formula based on the conceptual idea that combining anti-inflammatory signaling with aesthetic and tissue-repair peptides may address a broader set of research interests. This combined formulation has not been independently validated in clinical research.
Categories / Goals
Recovery & Repair
Metabolic Health
Weight Management
Performance
Muscle & Body Composition
Sleep & Recovery
Cognitive Health
Stress & Mood
Longevity & Healthy Aging
Cellular Energy
Skin, Hair & Aesthetics
Sexual Wellness
Search Tags (comma separated)
Last Reviewed Date
Display Order
Published
Featured
Save Peptide